Trial Profile
A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications COVID 2019 infections; Pneumonia
- Focus Adverse reactions; Therapeutic Use
- 13 Aug 2021 Status changed from completed to discontinued.
- 31 May 2021 Status changed from not yet recruiting to completed.
- 09 Apr 2020 Planned initiation date changed from 6 Apr 2020 to 20 Apr 2020.